# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2013 Earnings Results

**Report date:** 2013-08-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2013

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.1%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.73 | N/A | +100.46% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of optimism regarding future product developments. However, they acknowledged the competitive landscape.

**Key quotes:**

> Management highlighted ongoing research and development efforts.

> They expressed confidence in their pipeline despite market challenges.

### Guidance Changes

No guidance data was provided in this earnings report.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, but the stock fell by 6.1% in reaction. Investors may be concerned about the lack of revenue details and future guidance. The cautious tone from management suggests that while they are optimistic, there are challenges ahead that could impact growth.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2013_